Abstract:
Melasma is an acquired, symmetric, irregular hypermelanosis, common localized on face and is morefrequently observed among middle aged women.The etiology is unknown but many factor were involedin melasma.
Objective: to study the efficacy and side effect of topical 1% ellagicacid
Method: Volunteers 31 thai patients age 25-60 years old with epidermal and/or mixed melasma mostly famales (%) mean age 47.16±11.28 years. All patients we were included in a randomized, double- blind, placebo-controlled clinical trialto applied 1% ellagic acid cream on one side of face and a placebo cream on other side (applied twices a day) for 12 weeks and follow up every 4 weeks.
Result: at 12th week there is significant different in mean melanin index between topical 1% ellagic acid group and placebo group (p = 0.049) but no significant different in MASI score (p= 0.134). Topical 1% ellagic acid group significant decrease in mean melanin index and MASI score (p ‹ 0.001) every 4 weeks. 3 volunteers had minimal side effects and most satisfied.
Conclusion: there is significant different between topical 1% ellagic acid group and placebo group in treatment in melasma. There is a minimal side effects and most satisfied.